dabigatran has been researched along with Neoplasm Metastasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buijs, JT; Crooijmans, JJ; Kroone, C; Laghmani, EH; Le Dévédec, SE; Tieken, C; van den Akker, RFP; van der Molen, KM; van der Pluijm, G; Versteeg, HH; Vletter, EM | 1 |
| Alexander, ET; Gilmour, SK; Goss, A; Hayes, CS; Minton, AR; Van Ryn, J | 1 |
2 other study(ies) available for dabigatran and Neoplasm Metastasis
| Article | Year |
|---|---|
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Topics: Animals; Anticoagulants; Antithrombins; Breast Neoplasms; Cell Line, Tumor; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Rivaroxaban; Triple Negative Breast Neoplasms; Venous Thromboembolism; Xenograft Model Antitumor Assays | 2019 |
Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis.
Topics: Animals; Antineoplastic Agents, Alkylating; Antithrombins; Cell Line, Tumor; Cell-Derived Microparticles; Cyclophosphamide; Dabigatran; Disease Models, Animal; Disease Progression; Drug Synergism; Female; Mice; Myeloid Cells; Neoplasm Metastasis; Neoplasms; Platelet Activation; Thrombin; Thromboplastin | 2015 |